Alternatives to DNAnexus Apollo

GenomiX is an end-to-end genomics analytics platform designed to unify NHS-grade clinical genomics, flexible bioinformatics research, and AI-powered insights. It addresses the biggest challenges in the field, from handling massive raw sequencing files to harmonizing data across fragmented systems like EHRs, LIMS, and CRO platforms. Its cloud-agnostic and container-native architecture allows deployment on AWS, Azure, or GCP while supporting orchestration via Kubernetes and workflow engines such as Nextflow, CWL, and Snakemake. The platform delivers real-time data ingestion, tiered storage with lifecycle automation, and advanced metadata harmonization for structured insights. Integrated visualization tools and machine learning models like CNNs, BERT, and DESeq2 provide deeper analytics and predictive power. GenomiX also enables reproducibility with Git versioning, CI/CD pipelines, and customizable tool integration. Security is core, offering role-based access, full audit trails, NHS interoperability via FHIR, and certifications aligned with GDPR and HIPAA. By combining scalability, compliance, and innovation, GenomiX accelerates clinical research, enhances collaboration, and drives progress in personalized medicine.

Data-driven computational pipelines. Nextflow allows for reproducible and scalable scientific workflows by using software containers. It allows adaptation of scripts written in most common scripting languages. Fluent DSL makes it easy to implement and deploy complex reactive and parallel workflows on clusters and clouds. Nextflow was built on the belief that Linux is the lingua Franca of data science. Nextflow makes it easier to create a computational pipeline that can be used to combine many tasks. You can reuse existing scripts and tools. Additionally, you don't have to learn a new language to use Nextflow. Nextflow supports Docker, Singularity and other containers technology. This, together with integration of the GitHub Code-sharing Platform, allows you write self-contained pipes, manage versions, reproduce any configuration quickly, and allow you to integrate the GitHub code-sharing portal. Nextflow acts as an abstraction layer between the logic of your pipeline and its execution layer.

BigOmics Analytics is an innovative startup focused on biodata analytics, creating platforms that empower biologists to effectively visualize and interpret their omics data. Our primary offering, Omics Playground, is a highly intuitive bioinformatics tool tailored for RNA-seq and proteomics, enabling users to store their experimental data and visualize it interactively. With more than 18 interactive analysis modules and over 150 dynamic plots, the platform supports co-analysis with a vast array of more than 6,000 public datasets, in addition to providing access to more than 50,000 public gene sets and pathways. Furthermore, it seamlessly incorporates drug connectivity and drug sensitivity databases, featuring an extensive collection of over 30,000 drug expression profiles. BigOmics Analytics is designed to promote collaboration between biologists and bioinformaticians, allowing users to uncover insights while minimizing the time spent on data analysis, all without the need for any programming knowledge. The platform's commitment to producing reliable and reproducible results is achieved through the implementation of state-of-the-art methodologies. Ultimately, BigOmics Analytics is revolutionizing the way biological data is analyzed and understood.

Efficiently merge the multiomic information of patients with their health records to provide more tailored care solutions. Implement specialized data repositories to facilitate extensive analyses and foster collaborative research initiatives on a population-wide scale. Expedite research processes by leveraging adaptable workflows and comprehensive computational tools. Ensure the safeguarding of patient privacy through adherence to HIPAA standards, complete with robust data access and logging mechanisms. AWS HealthOmics empowers healthcare and life science organizations, along with their software collaborators, to securely store, retrieve, and analyze diverse omics data, such as genomic and transcriptomic information, ultimately yielding valuable insights that enhance health outcomes and propel scientific advancements. Manage and evaluate omics data for extensive patient cohorts to discern how variations in omics relate to phenotypic expressions within the population. Develop consistent and accountable clinical multiomics workflows designed to minimize turnaround times while boosting efficiency. Seamlessly incorporate multiomic assessments into clinical trials aimed at evaluating new therapeutic candidates, thereby enhancing the overall drug development process. By harnessing these innovative approaches, organizations can ensure a deeper understanding of patient health and contribute to groundbreaking research findings.

Our worldwide data-sharing network produces actionable clinical insights from data aimed at enhancing patient outcomes on a global scale. SOPHiA GENETICS is dedicated to shaping the future of AI-enhanced medicine. By integrating various healthcare-omics data types, we are dismantling existing data barriers and creating machine learning models that yield insights capable of aiding healthcare professionals in elevating patient care. The updated interface, along with new features and advanced functionalities, will further expedite precision medicine workflows, bringing us closer to making data-driven healthcare accessible to all. Utilizing the power of AI and machine learning (ML), our cloud-based platform offers a secure and easily accessible space for the standardization, computation, and analysis of digital health data, which generates insights from intricate multimodal data sets that can significantly enhance diagnostic processes, therapy choices, analytical methods, and drug development initiatives. Moreover, our continuous evolution reflects our commitment to innovation in the healthcare sector.

Aspect Analytics provides a spatial multi-omics platform designed for collaborative and interdisciplinary data analysis and management, catering to research teams engaged in drug development, biomarker discovery, pathology analysis, and more. This innovative platform empowers transformative research and enhances collaboration by aggregating multi-omics data into a unified, interactive interface. Users can overlay various spatial omics measurements in a single visualization, allowing for simultaneous insights. Our solution integrates data from all spatial multi-omics assays, ensuring that you derive the necessary insights efficiently. You can securely store and manage vast amounts of data, with the ability to access it from anywhere at any time. The platform is designed for scalability, enabling you to customize your data infrastructure based on specific requirements. It supports the integration of spatial biology data from a variety of technologies and vendors, regardless of the format of the data. Furthermore, you can establish automated workflows to conduct comprehensive analyses on extensive datasets concurrently, thus enhancing the efficiency and effectiveness of your research endeavors. This capability not only streamlines the research process but also fosters innovation across disciplines.

We are a biotechnology firm in the clinical stage, dedicated to unraveling biological complexities through the integration of cutting-edge innovations spanning biology, chemistry, automation, machine learning, and engineering, all aimed at revolutionizing drug discovery. Our approach allows for enhanced precision in biological manipulation with advanced techniques like CRISPR genome editing and synthetic biology. We also achieve reliable automation for intricate laboratory processes at an unprecedented scale through the use of sophisticated robotics. By employing neural network architectures, we conduct iterative analyses and draw insights from extensive, intricate datasets generated in-house. Furthermore, we are boosting the adaptability of high-performance computing capabilities through cloud-based solutions. Our initiative harnesses new technologies to foster continuous learning cycles around our datasets, establishing us as a next-generation biopharmaceutical enterprise. This is achieved through a harmonious integration of hardware, software, and data, all dedicated to the industrialization of drug discovery. We are transforming the conventional drug discovery pipeline and boast one of the most extensive, diverse, and in-depth pipelines among technology-driven drug discovery companies. Ultimately, our mission is to enhance the efficiency and effectiveness of drug development, paving the way for breakthrough therapies.

Manage, store, and collaborate on multi-omic datasets effectively. The Illumina Connected Analytics platform serves as a secure environment for genomic data, facilitating the operationalization of informatics and the extraction of scientific insights. Users can effortlessly import, construct, and modify workflows utilizing tools such as CWL and Nextflow. The platform also incorporates DRAGEN bioinformatics pipelines for enhanced data processing. Securely organize your data within a protected workspace, enabling global sharing that adheres to compliance standards. Retain your data within your own cloud infrastructure while leveraging our robust platform. Utilize a versatile analysis environment, featuring JupyterLab Notebooks, to visualize and interpret your data. Aggregate, query, and analyze both sample and population data through a scalable data warehouse, which can adapt to your growing needs. Enhance your analysis operations by constructing, validating, automating, and deploying informatics pipelines with ease. This efficiency can significantly decrease the time needed for genomic data analysis, which is vital when rapid results are essential. Furthermore, the platform supports comprehensive profiling to uncover novel drug targets and identify biomarkers for drug response. Lastly, seamlessly integrate data from Illumina sequencing systems for a streamlined workflow experience.

Correlation Engine serves as an engaging omics knowledgebase designed to situate private omics data within a rich biological framework alongside meticulously curated public datasets. Recognized as one of the most extensive biological databases globally, it offers life science researchers unparalleled access to an immense collection of high-quality whole-genome analyses, complemented by powerful scientific tools. This knowledgebase fosters groundbreaking discoveries by enabling the exploration of billions of data points sourced from standardized whole genome study analyses. It features an array of applications tailored for discerning biological context, a continuously expanding library of curated datasets, and versatility across various species and multi-omic datasets. Users can navigate through an intuitive graphical user interface that facilitates guided workflows, one-click applications, and application programming interfaces (APIs). By streamlining the transition from omic data to actionable insights, researchers can tap into over 25,000 multi-omics studies derived from more than 250,000 unique signatures that have undergone reanalysis, thereby enhancing their research capabilities even further.

Eidogen-Sertanty's Target Informatics Platform (TIP) stands out as the pioneering structural informatics system and knowledgebase that empowers researchers to explore the druggable genome through a structural lens. By harnessing the burgeoning wealth of experimental protein structure data, TIP revolutionizes structure-based drug discovery, shifting it from a limited, low-throughput field to a dynamic and data-rich scientific discipline. It is specifically designed to connect the realms of bioinformatics and cheminformatics, providing drug discovery scientists with a repository of insights that are not only unique but also highly synergistic with the information available from traditional bio- and cheminformatics tools. The platform's innovative combination of structural data management with advanced target-to-lead calculation and analytical capabilities significantly enhances every phase of the drug discovery process. With TIP, researchers are better equipped to navigate the complexities of drug development and make informed decisions.

OmicsBox, a leading bioinformatics tool, offers end-toend data analysis for genomes, transcriptomes and metagenomes. It also provides genetic variation studies. The application, which is used by leading private and public research institutes worldwide, allows researchers to process large and complicated data sets and streamline their analytical process. It is designed to be efficient, user-friendly and equipped with powerful tools to extract biological insight from omics data. The software is divided into modules, each of which has a set of tools and features designed to perform specific types of analyses, such as de novo genome assemblies, genetic variations analysis, differential expression analyses, taxonomic classifications, and taxonomic classes of microbiome, including the interpretation of results and rich visualizations. The functional analysis module uses the popular Blast2GO annotating methodology, making OmicsBox a great tool for non-model organisms research.

The Kanteron Platform assimilated a wide array of medical images, digital pathology slides, genomic sequences, and patient information from various modalities, scanners, sequencers, and databases, delivering a comprehensive data toolkit to all teams within hospital networks. It emphasizes pharmacogenomics to avert adverse medication events and facilitates the application of precision medicine at the point of care by integrating data sources on drug-gene interactions that were formerly only accessible in less user-friendly formats, such as tables found in PDF documents. By incorporating major pharmacogenomic databases like PharmGKB, CGI, DGIdb, and OpenTargets, it enables users to customize their queries according to specific gene families, types of interactions, and drug classifications. Additionally, its adaptable AI allows users to select the dataset that best aligns with their specific use case, applying it effectively to pertinent medical images. This robust functionality not only enhances the accuracy of medical insights but also fosters a more personalized approach to patient care.

At Genospace, we recognize that the evolution of precision medicine is being propelled by advancements in genomics, yet the challenge of effectively scaling its implementation remains unresolved. Our mission is to bridge this gap. Our innovative platform aims to transform biomedical data into valuable insights that are easily accessible for all, particularly for those actively involved in delivering care. Equip your clinicians and researchers with essential information that empowers them to make well-informed choices while participating in our goal of utilizing intricate molecular data to enhance patient outcomes and speed up the processes of drug development and research. In this context, the significance of large-scale population data for drug discovery and research cannot be overstated. Utilize cohort-driven analyses through the Genospace platform to support your research initiatives. We have a strong focus on clinical trial research, enabling the Genospace platform to seamlessly align fragmented patient information with intricate trial requirements, thus facilitating quicker patient recruitment. Furthermore, our platform is designed to integrate genomic medicine into standard clinical care practices, making it easier than ever to harness the power of genomics in everyday healthcare. Together, we can push the boundaries of what’s possible in patient care and research.

Revolutionize the fields of drug discovery and materials research through cutting-edge molecular modeling techniques. Our computational platform, grounded in physics, combines unique solutions for predictive modeling, data analysis, and collaboration, facilitating swift navigation of chemical space. This innovative platform is employed by leading industries globally, serving both drug discovery initiatives and materials science applications across various sectors including aerospace, energy, semiconductors, and electronic displays. It drives our internal drug discovery projects, overseeing processes from target identification through hit discovery and lead optimization. Additionally, it enhances our collaborative research efforts aimed at creating groundbreaking medicines to address significant public health challenges. With a dedicated team of over 150 Ph.D. scientists, we commit substantial resources to research and development. Our contributions to the scientific community include more than 400 peer-reviewed publications that validate the efficacy of our physics-based methodologies, and we remain at the forefront of advancing computational modeling techniques. We are steadfast in our mission to innovate and expand the possibilities within our field.

Rare diseases often lack comprehensive research, resulting in insufficient knowledge about essential elements for an effective drug discovery initiative. Our innovative AI platform, Healnet, addresses these issues by scrutinizing vast amounts of drug and disease data to uncover new connections that may lead to potential treatments. Utilizing cutting-edge technologies throughout the discovery and development process allows us to operate multiple phases simultaneously and on a large scale. The conventional approach of focusing on a single disease, target, and drug is overly simplistic, yet it remains the standard for most pharmaceutical companies. The future of drug discovery is driven by AI, characterized by parallel processes and an absence of rigid hypotheses, fundamentally integrating the three core paradigms of drug discovery into a cohesive strategy. This new paradigm not only enhances efficiency but also fosters creativity in developing solutions for complex health challenges.

Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.

Efficiently generating reports for NGS-based clinical tests necessitates a well-established and sophisticated platform that can automatically prioritize variants, interpret clinical data, and create comprehensive reports. Strand Omics serves as a rapid, HIPAA-compliant cloud platform that enhances our clinical diagnostics efforts, having been refined over four years through the analysis of more than 10,000 clinical reports and numerous peer-reviewed studies. This platform integrates advanced bioinformatics algorithms with curated databases, intuitive visualization tools, and robust reporting features. It is designed with specialized workflows tailored for both rare inherited conditions and somatic tumor profiling assays. Additionally, the system boasts a library of over 10,000 somatic variants that have been curated for their oncogenic potential, alongside 100 genes selected for their druggability across various cancer types, as well as 500 drugs that have been validated for efficacy against multiple cancers. Furthermore, its comprehensive approach ensures that healthcare professionals have access to critical data, ultimately facilitating informed decision-making in patient care.

Clara provides specialized tools and pre-trained AI models that are driving significant advancements across various sectors, such as healthcare technologies, medical imaging, pharmaceutical development, and genomic research. Delve into the comprehensive process of developing and implementing medical devices through the Holoscan platform. Create containerized AI applications using the Holoscan SDK in conjunction with MONAI, and enhance deployment efficiency in next-gen AI devices utilizing the NVIDIA IGX developer kits. Moreover, the NVIDIA Holoscan SDK is equipped with acceleration libraries tailored for healthcare, alongside pre-trained AI models and sample applications designed for computational medical devices. This combination of resources fosters innovation and efficiency, positioning developers to tackle complex challenges in the medical field.

Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.

AIDDISON™ is an innovative drug discovery software that harnesses the capabilities of artificial intelligence (AI), machine learning (ML), and advanced 3D computer-aided drug design (CADD) techniques, serving as an essential resource for medicinal chemistry applications. This comprehensive platform streamlines both ligand-based and structure-based drug design, effectively merging all components necessary for virtual screening while also facilitating in-silico lead discovery and optimization processes. By leveraging these cutting-edge technologies, AIDDISON™ significantly enhances the efficiency and effectiveness of the drug development pipeline.

Efficiently address tissue heterogeneity and the intricacies of microenvironments using the GeoMx Digital Spatial Profiler (DSP), which stands out as the most versatile and powerful spatial multi-omic platform for examining both FFPE and fresh frozen tissue sections. Unique among spatial biology platforms, GeoMx allows for non-destructive profiling of RNA and protein expression across various tissue compartments and cell populations, supported by an automated and scalable workflow that seamlessly integrates with conventional histology staining. You can spatially profile the entire transcriptome along with over 570 protein targets, either separately or concurrently, utilizing sample inputs such as whole tissue sections, tissue microarrays (TMAs), or organoids. By choosing GeoMx DSP, you position yourself at the forefront of spatial biology for effective biomarker discovery and hypothesis validation. With the ability to determine the relevant boundaries, you can rely on biology-driven profiling that enables you to focus on the tissue microenvironments and cell types that hold the most significance for your research. This innovative approach ensures that your analyses are both comprehensive and tailored to the specific biological contexts of interest.

LiveDesign serves as an integrated informatics solution that empowers teams to accelerate their drug discovery initiatives through collaborative design, experimentation, analysis, tracking, and reporting on a unified platform. It allows for the collection of innovative ideas alongside experimental and modeling data seamlessly. Users can develop and archive new virtual compounds within a centralized repository, assess them with sophisticated models, and prioritize the most promising designs. By merging biological data and model outputs from various corporate databases, the platform leverages advanced cheminformatics to provide a comprehensive analysis of all information simultaneously, facilitating quicker compound development. The platform employs cutting-edge physics-based methodologies along with machine learning to enhance prediction accuracy significantly. Teams can collaborate in real-time, regardless of location, enabling them to share concepts, conduct tests, make revisions, and progress chemical series while maintaining a clear record of their work. This not only fosters innovation but also ensures that projects remain organized and efficient throughout the drug discovery process.

Characterized by the exponential increase in data, integrated workloads, and ongoing digital transformation, the exascale era signifies a transformative phase of exploration that requires enhanced capabilities. To accommodate a spectrum of processor technologies and data-heavy tasks, new infrastructure is essential for seamlessly integrating analytics, AI, and high-performance computing (HPC), thereby unlocking the full potential of your data and fostering innovation. With HPE Apollo systems, you can tackle your most challenging problems while gaining cost-effective access to supercomputing power. These systems, designed for rack-scale efficiency, offer an ideal combination of performance and flexibility, making them specifically optimized for both HPC and AI applications. As you navigate your growth trajectory, HPE Apollo solutions allow you to adjust to diverse workloads seamlessly. The HPE Apollo 2000 Gen10 Plus system stands out by offering a space-efficient solution that accommodates up to four hot-plug servers within a 2U chassis, providing the versatility to customize the system to meet the specific demands of your rigorous HPC tasks while ensuring scalability for future needs. In this way, organizations can stay ahead in the rapidly evolving landscape of technology and data.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

Cytel stands out as a prominent global innovator in software for clinical trial design, biometrics, and advanced analytics, focusing on maximizing the efficiency of clinical trials while aiding pharmaceutical companies in harnessing the full scope of both clinical and real-world data. Established in 1987 by renowned statisticians Cyrus Mehta and Nitin Patel, Cytel has consistently been a leader in adaptive clinical trial technology and the field of biostatistics. Its software solutions, notably the East Horizon platform, facilitate accurate trial design and simulation, employing adaptive and Bayesian methodologies to enhance protocols and expedite the drug development process. The East Horizon platform serves as a comprehensive integration of Cytel's reliable software offerings, featuring R integration that significantly improves trial design functions. Furthermore, Cytel provides the Xact software suite, which is an all-encompassing toolkit designed for statistical analysis of small datasets, including those with sparse and missing data. By continuously innovating and expanding its product offerings, Cytel remains committed to providing cutting-edge solutions that meet the evolving needs of clinical research.

BC platforms harnesses cutting-edge scientific advancements, innovative technological capabilities, and strategic alliances to transform drug discovery and tailor healthcare solutions. Our platform is modular and highly adaptable, designed for integrating healthcare data effectively. With an open analytics framework, we seamlessly merge the most recent innovative methods and technology advancements into a single, cohesive platform. We prioritize security, holding ISO 27001 certification alongside compliance with GDPR and HIPAA regulations. Our comprehensive product suite empowers a contemporary healthcare system to fully adopt personalized medicine approaches. Our scalable deployment options support everything from initial setups to expansive healthcare operations. By offering a unique end-to-end toolbox, we facilitate the expedited application of research findings in clinical settings. Moreover, we strive to minimize your risks, enhance the value of your pipeline, and advance your enterprise data strategy by overcoming data access challenges and enabling swift insights. In doing so, we aim to foster a health ecosystem that is both responsive and forward-thinking.

We have established ourselves as frontrunners in the fields of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology, a status achieved through the achievements our clients have experienced while partnering with us. Leveraging over two decades of expertise, our skilled team excels at transforming complex scientific concepts into accessible software solutions, while also offering specialized consulting services that bolster drug discovery, clinical development research, and regulatory submission processes. Our dedication to client success drives our continuous improvement and innovation in these critical areas.

Scitara DLX™ provides a swift connectivity framework suitable for any instrument found within life science laboratories, all while operating on a cloud-based platform that is both compliant and auditable. As a versatile digital data infrastructure, Scitara DLX™ facilitates connections between various instruments, resources, applications, and software utilized in the lab. The comprehensive cloud system ensures that all data sources are interconnected, promoting seamless data movement across numerous endpoints. Consequently, researchers can concentrate on their scientific endeavors instead of being bogged down by data-related challenges. Moreover, DLX intelligently curates and corrects data as it is processed, fostering the creation of accurate and well-organized data models that are essential for enhancing AI and ML systems. This robust approach plays a vital role in advancing digital transformation strategies within the pharmaceutical and biopharmaceutical sectors. By unlocking valuable insights from scientific data, the platform accelerates decision-making processes in drug discovery and development, ultimately aiding in the expedited launch of new medications into the market. Additionally, the integration of such a sophisticated infrastructure not only streamlines workflows but also enhances collaboration among researchers, paving the way for innovative solutions in the life sciences field.

DNAnexus Titan™ is revolutionizing the field of genomics research and clinical workflows by offering reliable, high-performance data analysis solutions tailored for modern needs. Traditional informatics tools often struggle to cope with the increasing volumes of sequencing data generated today. Many research institutions and clinical diagnostic firms are grappling with the challenges posed by DIY systems, finding it laborious to establish, enhance, validate, and implement scalable pipelines. With DNAnexus Titan™, these hurdles are eliminated through a cohesive platform that integrates all data and workflows into a single environment, resulting in unmatched operational efficiencies. By entrusting us with the complexities of industry and region-specific security and compliance, you can focus on addressing the surging global demand for sequencing data without the burden of management challenges. Our platform not only simplifies the process but also enhances collaboration and accelerates scientific discovery.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

Uncover biological markers, generate insights into the mechanisms of disease, identify novel pharmaceuticals, or detect variations in protein concentrations through a meticulously structured series of experiments. We have simplified the process of harnessing the potential of mass spectrometry and proteomics, enabling you to concentrate on the intricacies of biology and advance toward groundbreaking discoveries. Our automated and consistent workflow facilitates faster initiation and completion of experiments, granting you the authority and adaptability to make timely decisions. By prioritizing biological insights and fostering collaborative efforts, our scalable proteomics data processing system is designed for repeated use. We have delegated intensive and repetitive tasks to the cloud, ensuring a smooth and satisfying experience. Our sophisticated proteomics workflow effectively integrates numerous complex elements, allowing for the efficient analysis and processing of larger-scale experiments, ultimately enhancing the research journey. Thus, with our innovative approach, researchers can now delve deeper into the molecular landscape and achieve more significant breakthroughs than ever before.

Numerous healthcare providers rely on Apollo by Crosby Health to create, submit, and monitor appeals, significantly alleviating the strain caused by clinical denials. With an advanced understanding of clinical contexts, Apollo outperforms all other medical language models on essential metrics. Its specialized training equips it to manage various billing tasks with exceptional accuracy, including auditing, charge capture, and denial management. As the fastest clinical language model available, it boasts the largest context length, generating outputs at an impressive rate of 60 words per second while processing documents of up to 300 pages. Our AI meticulously composes compelling appeal letters for every denial, maximizing the chances for recovery through well-structured arguments. By consolidating multiple payor portals and fax numbers into a single platform, Apollo simplifies the submission and tracking of every appeal. Furthermore, it effectively reduces the burden on providers by automating the appeal generation process and is adept at pinpointing medical necessity within documentation. With just one click, providers can submit appeals to any insurance company seamlessly. This innovative solution not only streamlines the process but also enhances the overall efficiency of healthcare administration.

Qlucore Omics Explorer is designed to be user-friendly, eliminating the necessity to rely on bioinformatics experts for the exploration and analysis of your Omics and NGS datasets. This software serves as a do-it-yourself solution for next-generation bioinformatics in life sciences, plant and biotechnology sectors, and educational institutions. It features a robust and adaptable visualization-based data analysis tool that incorporates advanced statistical methods, yielding instant results and enabling immediate exploration and visualization of extensive data sets. Built to accommodate workflows that align with your research needs, it enhances the effectiveness of your studies. By merging real-time visualization with sophisticated statistical techniques and flexible selection options, you can promptly observe your findings. As a user, you have the autonomy to determine your own workflow and starting point, allowing for a customized exploration that aligns with your unique requirements. This level of control empowers researchers to tailor their analyses, ensuring that the software adapts seamlessly to diverse experimental designs.

BIOiSIMTM represents a groundbreaking 'virtual drug development engine' that significantly enhances the drug development sector by effectively identifying drug compounds that are most likely to provide meaningful therapeutic benefits for various diseases or conditions. We provide an array of translational solutions that are tailored to meet the specific needs of your pre-clinical and clinical initiatives. Central to our offerings is the highly validated BIOiSIMTM platform, which supports the development of small molecules, large molecules, and viruses. This innovative platform is underpinned by extensive data derived from thousands of compounds across seven different species, resulting in a level of robustness that is uncommon in the field. Emphasizing human health outcomes, the heart of the platform features a translatability engine that seamlessly converts insights gained from different species. Importantly, the BIOiSIMTM platform can be deployed prior to the initiation of preclinical animal trials, facilitating earlier insights and potentially reducing the costs associated with outsourced experimentation. By integrating these advanced capabilities, we aim to streamline the drug development process and accelerate the journey from discovery to market.

Founded in 2000, VeraChem LLC aims to enhance the field of computer-aided drug discovery and molecular design by creating advanced computational chemistry techniques that merge innovative basic science with practical applications in research. A key aspect of the company's strategy for product development lies in delivering efficient, high-performance software solutions along with extensive user support. Among the current capabilities of VeraChem's software are predictions for protein-ligand and host-guest binding affinities, rapid and precise calculations of partial atomic charges for drug-like molecules, and the computation of energies and forces utilizing widely-used empirical force fields. Additionally, the software features automatic generation of alternate resonance forms for drug-like compounds, a robust conformational search enabled by the Tork algorithm, and the automatic identification of topological and three-dimensional molecular symmetries. The modular code base of VeraChem’s software packages allows for flexibility and adaptability in meeting diverse research needs, ensuring that users can leverage these tools effectively for their specific applications.

The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.

Discngine Assay serves as a comprehensive laboratory informatics platform that unifies all stages of plate-based assays into a streamlined, compliant, and effective workflow, proving to be a vital resource for screening research laboratories. This platform empowers researchers to optimize their entire High Throughput Screening process, encompassing everything from managing samples and analyzing assay data to data storage and qualifying liquid handling instruments. With its user-friendly interface and powerful API, Discngine Assay integrates effortlessly with laboratory equipment and the existing IT infrastructure, facilitating effective data collection and processing. Tailored to expedite the discovery of new molecules, it meets the requirements of the pharmaceutical, biotech, and contract research organization sectors, thereby promoting collaboration and fostering innovation within life sciences research. Furthermore, its ability to adapt to various laboratory environments makes it a versatile solution for evolving research demands.

Genedata Biologics® enhances the development of biotherapeutics, including bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, providing a comprehensive solution for the industry. Recognized as the leading platform in the field, it seamlessly unifies all discovery workflows, allowing researchers to prioritize genuine innovation. By utilizing a pioneering platform that was purposefully created to digitalize the biotherapeutic discovery process, research can be accelerated significantly. The platform simplifies intricate R&D tasks by facilitating the design, tracking, testing, and evaluation of novel biotherapeutic drugs. It is compatible with various formats, such as antibodies, bi- or multi-specifics, ADCs, innovative scaffolds, and therapeutic proteins, as well as engineered therapeutic cell lines like TCRs and CAR-T cells. Functioning as a comprehensive end-to-end data backbone, Genedata Biologics connects all R&D processes, including library design, immunization, selection and panning, molecular biology, screening, protein engineering, expression, purification, and protein analytics, ultimately leading to thorough assessments of candidate developability and manufacturability. This holistic integration ensures that researchers can make informed decisions and push the boundaries of biotherapeutic innovation effectively.

3decision® serves as a cloud-based repository for protein structures, focusing on efficient management of structural data and offering sophisticated analytics to support teams involved in the discovery of small molecules and biologics, thereby expediting the process of structure-based drug design. The platform consolidates and standardizes both experimental and computational protein structures sourced from publicly available databases such as RCSB PDB and AlphaFoldDB, in addition to proprietary datasets, and accommodates formats like PDBx/mmCIF and ModelCIF. This comprehensive approach guarantees seamless access to a variety of structural formats including X-Ray, NMR, cryo-EM, and modeled structures, thereby promoting collaboration and bolstering research initiatives. In addition to its storage capabilities, 3decision® enhances each entry with valuable metadata and sequence information, which encompasses details on protein-ligand interactions, antibody annotations, and specifics about binding sites. Equipped with advanced analytical instruments, the platform is capable of pinpointing druggable sites, evaluating off-target risks, and facilitating comparisons of binding sites, which collectively transform extensive structural datasets into practical insights that can drive research forward. Furthermore, its cloud-based architecture fosters enhanced collaboration among research teams, making it easier for scientists to share findings and insights, ultimately leading to more innovative approaches in drug discovery and development.

Delve into a vast collection of meticulously curated single-cell transcriptome datasets, as well as your own, using dynamic visualizations and analytical tools. This software is versatile, accommodating multimodal omics, CITE-seq, TCR-seq, and spatial transcriptomics. Engage with the most extensive single-cell expression database globally, where you can access and extract insights from a repository featuring millions of fully annotated cells complete with cell type labels and experimental metadata. Beyond merely serving as a conduit to published research, BioTuring Browser functions as a comprehensive end-to-end solution tailored for your specific single-cell data needs. Easily import your fastq files, count matrices, or Seurat and Scanpy objects to uncover the biological narratives contained within. With an intuitive interface, you can access an extensive array of visualizations and analyses, transforming the process of extracting insights from any curated or personal single-cell dataset into a seamless experience. Additionally, the platform allows for the importation of single-cell CRISPR screening or Perturb-seq data, enabling users to query guide RNA sequences with ease. This functionality not only enhances research capabilities but also facilitates the discovery of novel biological insights.

Business intelligence in the global biopharmaceutical sector focuses on drug patent dynamics and the entry of generics. It is essential to forecast future budget needs and proactively seek out generic alternatives. Analyzing the achievements of past patent challengers provides insights into the competitive landscape and informs research directions. This analysis plays a crucial role in guiding portfolio management strategies for upcoming drug development projects. Additionally, anticipating the expiration of patents on branded drugs, pinpointing potential generic suppliers, and managing branded drug inventory effectively are vital. Furthermore, acquiring detailed formulation and manufacturing data helps in identifying key formulators, repackagers, and relabelers to streamline operations and enhance market positioning. Understanding these elements can significantly bolster strategic decision-making in the biopharmaceutical industry.

Apollo is the platform for your entire end-to-end sales strategy. Sellers and marketers use Apollo to discover more customers in market, connect with contacts, and establish a modern go-to-market strategy.

The innovative XetaBase platform streamlines tertiary analysis by aggregating, indexing, and enriching secondary genomic data, which facilitates ongoing re-evaluation to reveal valuable insights for research and clinical applications. By enhancing data management practices, XetaBase allows for the economical utilization of genomic information both in laboratories and clinical settings. The platform is designed to handle expansive genomic datasets, where increased volume and complexity lead to improved insights and outcomes. Built on the open-source OpenCB software framework, XetaBase is a genomic-native technology that addresses the demands for scalability, speed, and innovative re-interpretation in genomic medicine. Zetta Genomics provides an advanced genomic data management solution tailored for the era of precision medicine. This transformative platform eliminates outdated flat file methods, introducing actionable and relevant genomic data into both laboratory and clinical environments. Furthermore, XetaBase not only supports ongoing re-interpretation but also adapts effortlessly as databases expand to include more comprehensive genome sequences, ensuring that users stay at the forefront of genomic advancements.

Enhance research outcomes while boosting team efficiency by utilizing interactive data visualization to extend both private and public datasets among various teams. Rosalind stands out as the sole multi-tenant SaaS platform tailored for scientists, enabling the analysis, interpretation, sharing, planning, validation, and generation of new hypotheses with ease. It offers code-free visualization and employs AI for interpretation, fostering top-tier collaboration among users. Regardless of their expertise, scientists can leverage ROSALIND effectively, as it requires no programming or bioinformatics knowledge. The platform serves as a robust discovery tool and data hub, seamlessly integrating experiment design, quality control, and pathway analysis. ROSALIND's advanced infrastructure automatically orchestrates tens of thousands of compute cores and manages petabytes of storage, scaling resources dynamically for each experiment to ensure timely results. Furthermore, scientists can effortlessly share their findings with peers worldwide, complete with audit tracking to prioritize interpretation over data processing, thereby fostering a more collaborative research environment. This unique combination of features empowers researchers to focus on innovation and scientific discovery.

The software designed to enhance safety, traceability, quality, agility, and integration within your Pharmacotechnics and Medicines Manufacturing Unit is here to assist you. Recognizing that each pharmacy service is unique, we have structured PharmaSuite into specialized functional modules tailored to optimize the management of various units effectively. This includes the oversight of the Pharmacotechnics and Drug Preparation unit, specifically for parenteral mixtures, as well as the administration of parenteral nutrition. With these tools, you can streamline operations and ensure compliance with industry standards.